# breast cancer - deepseek-v4-flash

- Benchmark system: E2seq + Agent RAG
- Repeat: 5
- Task type: PROGNOSIS
- Tissue / sample source: breast tumor tissue
- Comparison or endpoint: overall survival (OS)
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: DeepSeek / deepseek-v4-flash
- Message SHA-256: 2eef237c25053f55d87c73e963368cae88b5c698447f11e7e98ebc594d62e5bb
- Response HTTP status: 200
- Prompt tokens: 30878
- Completion tokens: 13061
- Reasoning tokens: 0
- Total tokens: 43939
- API requests reported: 2
- Elapsed seconds: 285.688
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 685.605
- Question handoff seconds: 699.996
- Final benchmark system: E2seq; file rank 4/5; original repeat 5; model vendor: DeepSeek

---
# Multidimensional biological interpretation of the prognostic transcriptomic signature in breast cancer (OS endpoint)

## 1. Overall biological interpretation

The uploaded survival analysis (100 unique genes, all with FDR ≤ 0.01) defines a prognostic transcriptomic architecture in breast tumor tissue in which **higher expression of cell-cycle and proliferation machinery is the dominant risk-associated signal**, while **protective association clusters around immune, stromal, and differentiation-related genes**.

The risk-associated genes (HR > 1) form a highly coherent block: mitotic regulators (`AURKA`, `TPX2`, `KIF20A`, `KIF4A`, `CDC20`, `CDCA5`, `ZWINT`, `CENPO`, `CKAP2L`, `NUSAP1`, `PRC1`, `PTTG1`, `UBE2C`, `UBE2S`), DNA replication/repair factors (`FEN1`, `TIMELESS`, `RPA2` is protective, `UHRF1`), and cell-cycle checkpoint/kinase genes (`PKMYT1`, `CCNE2`, `GSK3B`). This block is consistent with a proliferation-driven aggressive phenotype.

The protective-associated genes (HR < 1) cluster around: immune cell markers (`FCER1A`, `CD1C`, `CD1E`, `JCHAIN`, `KLRB1`, `IL27RA`, `FLT3`), extracellular matrix / stromal components (`COL17A1`, `COL14A1`, `LAMA2`, `ADAMTS8`, `MFAP4`, `OGN`, `OMD`, `RELN`), and differentiation/hormone-related genes (`STAT5A`, `STAT5B`, `IGF1`, `IGFBP6`, `LEPR`, `TP63`, `CCND2`). This block is consistent with an immune-competent, less proliferative tumor microenvironment.

The overall picture is that **the transcriptomic signature separates patients primarily along a proliferation axis versus an immune/stromal/differentiation axis**, with the former conferring worse and the latter conferring better overall survival.

## 2. Core biological programs

### Program 1: Mitotic spindle assembly and chromosome segregation
- **Direction**: Risk-associated (higher expression → worse OS)
- **Supporting genes**: `AURKA`, `TPX2`, `KIF20A`, `KIF4A`, `CDC20`, `CDCA5`, `ZWINT`, `CENPO`, `CKAP2L`, `NUSAP1`, `PRC1`, `PTTG1`, `RACGAP1`, `TROAP`
- **Pathway**: KEGG Cell cycle; Reactome "Mitotic Prometaphase" / "Resolution of Sister Chromatid Cohesion"
- **Rationale**: Multiple genes encode proteins with well-defined roles in spindle pole organization (AURKA/TPX2), kinesin-mediated chromosome movement (KIF20A, KIF4A), kinetochore attachment (ZWINT, CENPO), and sister chromatid separation (CDC20, PTTG1). The STRING network evidence shows a densely connected module centered on PLK1 and TPX2 with selected genes (AURKA, CDC20, KIF20A, PKMYT1; AURKA, KIF4A, NUSAP1, PRC1), consistent with pathway co-membership and documented physical interactions.
- **Evidence strength**: Strong. The uploaded statistics are highly significant (all FDR < 1.3e-06) and the genes are functionally coherent. The main limitation is that this is a survival association, not a causal demonstration; additionally, the STRING edges are database-derived and may reflect shared pathway membership rather than direct physical interaction in breast cancer specifically.

### Program 2: DNA replication, repair, and cell-cycle checkpoint
- **Direction**: Risk-associated (higher expression → worse OS)
- **Supporting genes**: `FEN1`, `TIMELESS`, `UHRF1`, `PKMYT1`, `CCNE2`, `TK1`, `RPA2` (protective, see note)
- **Pathway**: GO "DNA replication"; KEGG Cell cycle; Reactome "Cell Cycle Checkpoints"
- **Rationale**: FEN1 is a flap endonuclease in Okazaki fragment processing; TIMELESS participates in replication fork stability; UHRF1 links DNA methylation to replication (maintaining epigenetic marks); PKMYT1 is a G2/M checkpoint kinase; CCNE2 drives G1/S transition; TK1 is a nucleotide salvage enzyme. These genes collectively indicate an active replication program.
- **Evidence strength**: Moderate-to-strong. The genes are individually significant, but the program overlaps with the proliferation axis (Program 1) and is not fully independent. Note that `RPA2` (single-strand DNA binding protein, replication factor) is protective-associated in this dataset, which is a direction conflict that complicates a simple "replication = risk" interpretation.

### Program 3: Immune cell infiltration / antigen presentation
- **Direction**: Protective-associated (higher expression → better OS)
- **Supporting genes**: `FCER1A`, `CD1C`, `CD1E`, `JCHAIN`, `KLRB1`, `IL27RA`, `FLT3`, `STAT5A`, `STAT5B`
- **Pathway**: GO "antigen processing and presentation"; Hallmark "IL6-JAK-STAT3 signaling" (partial); KEGG "Hematopoietic cell lineage"
- **Rationale**: CD1C/CD1E are lipid antigen-presenting molecules on dendritic cells; FCER1A is the high-affinity IgE receptor on dendritic cells/basophils; JCHAIN encodes the joining chain of IgM/IgA; KLRB1 (CD161) marks innate-like lymphocytes; FLT3 is a dendritic cell growth factor receptor; IL27RA is an immune-regulatory cytokine receptor. The STAT5A/STAT5B protective association is consistent with their role in immune cell development and differentiation.
- **Evidence strength**: Moderate-to-strong. The uploaded statistics are highly significant and the gene set is functionally coherent. The main limitation is that **tumor purity and stromal/immune cell composition** may drive these associations; the signal may reflect the proportion of infiltrating immune cells in the bulk tumor tissue rather than tumor-cell-intrinsic biology.

### Program 4: Extracellular matrix and stromal remodeling
- **Direction**: Protective-associated (higher expression → better OS)
- **Supporting genes**: `COL17A1`, `COL14A1`, `LAMA2`, `ADAMTS8`, `MFAP4`, `OGN`, `OMD`, `RELN`, `IGSF10`, `PDGFRA`
- **Pathway**: GO "extracellular matrix organization"; Reactome "ECM proteoglycans"; KEGG "ECM-receptor interaction"
- **Rationale**: These genes encode collagen subtypes (COL17A1, COL14A1), a laminin subunit (LAMA2), a matrix metalloprotease family member (ADAMTS8), and small proteoglycans (OGN, OMD). The protective direction suggests that a differentiated, matrix-rich microenvironment is associated with better survival, possibly reflecting a less aggressive tumor-stroma interaction.
- **Evidence strength**: Moderate. The uploaded statistics are significant, but the interpretation is complicated by the fact that ECM genes are expressed by stromal cells (fibroblasts, adipocytes) and the signal may reflect stromal content rather than tumor-cell biology. The protective direction is noteworthy but requires validation in cell-type-resolved data.

### Program 5: Metabolism and stress response
- **Direction**: Mixed (risk: `CPT1A`, `GPI`, `TRIB3`, `GSK3B`; protective: `GSTK1`, `GLA`, `AK3`, `ABCB1`)
- **Supporting genes**: `CPT1A`, `GPI`, `TRIB3`, `GSK3B`, `GSTK1`, `GLA`, `AK3`, `ABCB1`, `CPT1A`
- **Pathway**: KEGG "Fatty acid degradation" (CPT1A); KEGG "Glycolysis/Gluconeogenesis" (GPI); GO "response to oxidative stress" (GSTK1)
- **Rationale**: CPT1A (carnitine palmitoyltransferase 1A) is the rate-limiting enzyme of mitochondrial fatty acid oxidation; GPI is a glycolytic enzyme; TRIB3 is a stress-responsive pseudokinase; GSK3B is a multifunctional kinase in Wnt and insulin signaling; GSTK1 is a glutathione transferase; ABCB1 encodes a drug efflux transporter. The mixed direction makes this program less coherent than the others.
- **Evidence strength**: Weak-to-moderate. The genes are individually significant, but the program is not biologically coherent in direction. This may reflect multiple distinct metabolic processes rather than a single program; it should be treated as exploratory.

## 3. Key genes and interaction modules

### Module 1: AURKA–TPX2–KIF4A–NUSAP1–PRC1 (mitotic spindle module)
- **Statistical direction**: All risk-associated (AURKA HR=1.189, TPX2 HR=1.202, KIF4A HR=1.199, NUSAP1 HR=1.194, PRC1 HR=1.186; all FDR < 1.3e-06)
- **Role**: Core mitotic spindle assembly and cytokinesis machinery.
- **Interaction nature**: STRING records show TPX2 as a hub with edges to AURKA, KIF4A, NUSAP1, PRC1. TPX2 is a well-documented direct physical activator of AURKA in spindle pole assembly; KIF4A is a kinesin that interacts with the AURKA/TPX2 complex during spindle organization. NUSAP1 and PRC1 are spindle-associated proteins with documented interactions in the mitotic apparatus. These are **direct physical interactions** supported by structural/functional studies, though the STRING edges alone are database-derived.
- **Evidence**: Direct (uploaded HR/FDR) + protein interaction (STRING, IntAct) + pathway (KEGG Cell cycle).

### Module 2: CDC20–UBE2C–UBE2S–PTTG1 (APC/C module)
- **Statistical direction**: All risk-associated (CDC20 HR=1.191, UBE2C HR=1.210, UBE2S HR=1.184, PTTG1 HR=1.197; all FDR < 5.0e-07)
- **Role**: Anaphase-promoting complex/cyclosome (APC/C) co-activator and ubiquitin-conjugating enzymes that drive mitotic exit and sister chromatid separation.
- **Interaction nature**: STRING shows CDC20 with edges to PTTG1, UBE2C, UBE2S; ANAPC2 (APC/C core subunit) with edges to CDC20, UBE2C, UBE2S. CDC20 is a direct physical co-activator of APC/C; UBE2C and UBE2S are E2 enzymes that work with APC/C. This is a **direct physical interaction / pathway co-membership** module (the APC/C complex is a multi-subunit E3 ligase).
- **Evidence**: Direct (uploaded) + protein interaction (STRING) + pathway (KEGG Cell cycle, GO "positive regulation of ubiquitin-protein ligase activity").

### Gene 3: GSK3B (risk-associated)
- **Statistical direction**: Risk-associated (HR=1.227, FDR=1.16e-09)
- **Role**: Serine/threonine kinase with roles in Wnt/β-catenin signaling, cell-cycle regulation, and metabolism. STRING records show high-confidence interactions with APC, AXIN1, CTNNB1, DVL1, BTRC — consistent with its role in the β-catenin destruction complex.
- **Interaction nature**: Direct physical interactions with APC, AXIN1, CTNNB1 are well documented (destruction complex components). The risk-associated direction is plausible given GSK3B's role in priming β-catenin for degradation (loss of function → Wnt activation), but the direction in breast cancer survival is context-dependent.
- **Evidence**: Direct (uploaded) + protein interaction (STRING) + pathway (KEGG Cell cycle, Wnt signaling).

### Module 4: STAT5A–STAT5B–FLT3–LEPR–IL27RA (JAK-STAT immune module)
- **Statistical direction**: All protective-associated (STAT5A HR=0.806, STAT5B HR=0.837, FLT3 HR=0.817, LEPR HR=0.821, IL27RA HR=0.825; all FDR < 4.7e-07)
- **Role**: JAK-STAT signaling in immune cell development, differentiation, and cytokine responses.
- **Interaction nature**: STRING shows STAT3 as a hub with edges to FLT3, LEPR, STAT5A, STAT5B. STAT5A/B are transcription factors activated downstream of cytokine receptors (including FLT3 and LEPR). These are **regulatory interactions** (receptor → kinase → STAT transcription factor), not necessarily direct physical binding.
- **Evidence**: Direct (uploaded) + STRING network + literature (JAK-STAT pathway is well characterized).

### Gene 5: LARP1 (risk-associated, top HR)
- **Statistical direction**: Risk-associated (HR=1.261, FDR=4.48e-10; strongest HR in the cohort)
- **Role**: RNA-binding protein that regulates translation of 5′TOP mRNAs (including ribosomal proteins and translation factors) downstream of mTORC1.
- **Interaction nature**: Not a clear module member in this cohort; it is a single-gene signal. Its role is consistent with a translation/ribosome biogenesis program linked to proliferation.
- **Evidence**: Direct (uploaded) + RNA binding annotation (QuickGO) + literature (mTORC1-LARP1 axis). The interaction with other selected genes is **indirect/putative** (shared pathway membership in translation control, not directly supported by the retrieved interaction records).

### Gene 6: STIP1 (risk-associated)
- **Statistical direction**: Risk-associated (HR=1.237, FDR=9.74e-10)
- **Role**: Co-chaperone (HOP) that links Hsp70 and Hsp90, facilitating client protein maturation. Literature from the retrieved context (PMID 37488801) links STIP1 to tumor immune infiltration and prognosis in pan-cancer analyses.
- **Interaction nature**: STIP1 participates in a chaperone complex with HSP70/HSP90 (direct physical interaction); its relationship to other selected genes is **indirect/putative** (chaperone function supports many client proteins).
- **Evidence**: Direct (uploaded) + literature (PMID 37488801) + protein interaction (STRING/IntAct records for chaperone partners, not shown in the top retrieved chunks but annotated).

### Gene 7: S100P (risk-associated)
- **Statistical direction**: Risk-associated (HR=1.196, FDR=5.41e-07)
- **Role**: Calcium-binding protein implicated in tumor progression and metastasis in multiple cancers.
- **Interaction nature**: Not a clear module member in this cohort; the relationship to other selected genes is **indirect/putative**.
- **Evidence**: Direct (uploaded) + literature (S100P is a well-studied cancer biomarker).

### Gene 8: FCER1A / CD1C / CD1E / JCHAIN (protective immune markers)
- **Statistical direction**: All protective-associated (FCER1A HR=0.793, CD1C HR=0.814, CD1E HR=0.824, JCHAIN HR=0.803; all FDR < 1.8e-09)
- **Role**: Markers of dendritic cells (FCER1A, CD1C, CD1E) and antibody-producing plasma cells (JCHAIN). Their protective association is consistent with immune infiltration being beneficial.
- **Interaction nature**: These genes are **co-expressed** in the same cell types (dendritic cells, B cells/plasma cells) but are not necessarily direct physical interactors. Their co-occurrence in this signature likely reflects cell-type composition.
- **Evidence**: Direct (uploaded) + tissue/cell-type annotation (HPA, GTEx) + literature. The protective direction is consistent with the well-established prognostic benefit of immune infiltration in breast cancer.

### Gene 9: PROS1 (protective-associated)
- **Statistical direction**: Protective-associated (HR=0.836, FDR=1.08e-06)
- **Role**: Protein S, a coagulation factor and TAM receptor ligand (Tyro3/Axl/MerTK). The retrieved literature (PMID 37827342) reports PROS1 as a prognostic biomarker associated with immune cell infiltration in breast cancer.
- **Interaction nature**: PROS1 interacts with TAM receptors (regulatory interaction); its relationship to other selected genes is **indirect/putative** (immune modulation).
- **Evidence**: Direct (uploaded) + breast-cancer-specific literature (PMID 37827342).

### Module 10: GPRC5A–ADGRG1–GPI–CFL1 (risk-associated, mixed functions)
- **Statistical direction**: All risk-associated (GPRC5A HR=1.202, ADGRG1 HR=1.205, GPI HR=1.192, CFL1 HR=1.191; all FDR < 9.6e-07)
- **Role**: GPRC5A is an orphan GPCR implicated in multiple cancers (literature: PMID 40865843, gastric cancer glycolysis-related biomarker); ADGRG1 (GPR56) is an adhesion GPCR; GPI is a glycolytic enzyme; CFL1 is an actin-depolymerizing factor. These genes are not functionally coherent as a module; they likely represent distinct processes (GPCR signaling, glycolysis, actin dynamics) that each contribute to aggressive behavior.
- **Interaction nature**: **Pathway co-membership** or **indirect/putative** relationships; no strong direct interaction evidence was retrieved.
- **Evidence**: Direct (uploaded) + literature for individual genes.

## 4. Validation priorities

### Priority 1: Proliferation signature as a prognostic biomarker
- **Classification**: Biomarker
- **Why**: The mitotic spindle / APC/C module (AURKA, TPX2, CDC20, UBE2C, ZWINT, etc.) is the most coherent and statistically robust risk-associated signal in the dataset. A composite proliferation score could be clinically useful.
- **Current dataset evidence**: 15+ genes with HR > 1.18 and FDR < 1.3e-06.
- **External evidence**: Proliferation signatures (e.g., the "CIN70" or "proliferation cluster" in PAM50) are established prognostic factors in breast cancer; individual genes (AURKA, CDC20, UBE2C) have prior literature support.
- **Next step**: Build a composite score from the mitotic genes, test in an independent breast cancer cohort with OS data (e.g., METABRIC, TCGA-BRCA), and compare against established proliferation scores (e.g., Ki67, PAM50 proliferation score).
- **Conclusion status**: **Supported hypothesis** (the association is established in this dataset; external validation is required for clinical use).

### Priority 2: Immune cell composition as the driver of protective associations
- **Classification**: Confounding or composition check
- **Why**: The protective genes (CD1C, CD1E, FCER1A, JCHAIN, KLRB1, FLT3, IL27RA) are almost certainly expressed by infiltrating immune cells rather than tumor cells. The protective association may reflect immune infiltration, which is a known favorable prognostic factor in breast cancer.
- **Current dataset evidence**: 10+ immune-related protective genes with FDR < 5e-07.
- **External evidence**: Established literature on immune infiltration and prognosis in breast cancer; the retrieved literature on PROS1 (PMID 37827342) and STIP1 (PMID 37488801) both link immune infiltration to prognosis.
- **Next step**: Estimate immune/stromal scores (ESTIMATE, CIBERSORT, MCP-counter) from the same expression data; test whether the protective associations persist after adjusting for immune cell proportions. Validate in single-cell data to confirm cell-type-specific expression.
- **Conclusion status**: **Exploratory hypothesis** — the composition hypothesis is plausible but not directly tested in the current data.

### Priority 3: AURKA–TPX2 axis as a therapeutic target
- **Classification**: Therapeutic target
- **Why**: AURKA is a druggable kinase with selective inhibitors in clinical development; the AURKA–TPX2 interaction is a validated dependency in multiple cancers.
- **Current dataset evidence**: AURKA (HR=1.189), TPX2 (HR=1.202), KIF4A (HR=1.199) all risk-associated with FDR < 7.3e-07; STRING shows TPX2–AURKA interaction.
- **External evidence**: AURKA inhibitors (e.g., alisertib) have been tested in breast cancer clinical trials; the TPX2–AURKA interaction is structurally characterized. However, **the existence of a drug does not imply efficacy** — the current data only support an association, not a causal dependency.
- **Next step**: Test AURKA/TPX2 expression correlation with drug sensitivity in cell lines (e.g., GDSC, CCLE); test whether AURKA inhibition selectively kills AURKA/TPX2-high breast cancer cells in vitro.
- **Conclusion status**: **Exploratory hypothesis** — the association is real but the therapeutic hypothesis requires functional validation.

### Priority 4: GSK3B–β-catenin axis as a mechanistic hypothesis
- **Classification**: Mechanistic hypothesis
- **Why**: GSK3B is a central node in Wnt/β-catenin signaling and interacts with APC, AXIN1, CTNNB1 (STRING, confidence=0.999). Its risk-associated direction is biologically plausible but context-dependent.
- **Current dataset evidence**: GSK3B HR=1.227, FDR=1.16e-09.
- **External evidence**: GSK3B has dual roles (tumor suppressor in Wnt degradation complex; oncogenic in other contexts); the direction in breast cancer is debated.
- **Next step**: Examine GSK3B protein expression and phosphorylation status; test whether GSK3B expression correlates with nuclear β-catenin in the same tumors; perform GSK3B knockdown/overexpression in breast cancer cell lines to assess proliferation.
- **Conclusion status**: **Exploratory hypothesis** — the association is clear but the mechanism is not established by the current data.

### Priority 5: ECM/stromal protective signature — cell-type-resolved validation
- **Classification**: Confounding or composition check
- **Why**: The ECM genes (COL17A1, COL14A1, LAMA2, OGN, OMD, MFAP4) are stromal-expressed; their protective association may reflect stromal content or a differentiated tumor phenotype.
- **Current dataset evidence**: 10+ ECM genes with protective HR < 0.83, FDR < 1.1e-06.
- **External evidence**: Stromal signatures have variable prognostic associations in breast cancer; some ECM genes (e.g., COL17A1) are associated with differentiated luminal biology.
- **Next step**: Use spatial transcriptomics or single-cell data to determine which cell types express these genes; test whether the protective association is independent of stromal proportion estimates.
- **Conclusion status**: **Exploratory hypothesis** — the association is present but the biological interpretation is uncertain.

## 5. Evidence grounding

| Claim | Direct (uploaded) | Pathway/ontology | Protein interaction | Disease association | Literature | Independent cohort |
|---|---|---|---|---|---|---|
| Mitotic/proliferation genes are risk-associated | Yes (HR>1, FDR<1.3e-06) | Yes (KEGG Cell cycle, GO mitotic division) | Yes (STRING: PLK1, TPX2, ANAPC2 hubs) | Yes (cBioPortal, ClinVar, CIViC records) | Yes (multiple) | **No** (not performed) |
| Immune genes are protective-associated | Yes (HR<1, FDR<5e-07) | Yes (GO antigen presentation) | Partial (STAT3 hub) | Yes (cBioPortal) | Yes (PMID 37827342, 37488801) | **No** |
| ECM genes are protective-associated | Yes (HR<1, FDR<1.1e-06) | Yes (GO ECM organization) | Limited | Partial | Partial | **No** |
| AURKA–TPX2 interaction | No (not measured) | Yes (KEGG Cell cycle) | Yes (STRING, IntAct) | Yes | Yes | **No** |
| GSK3B–β-catenin mechanism | No (only HR) | Yes (KEGG Cell cycle, Wnt) | Yes (STRING: APC, AXIN1, CTNNB1) | Partial | Yes (context-dependent) | **No** |

**Important caveats on evidence independence**: The pathway annotations (GO, KEGG, Reactome) and the protein interaction records (STRING, IntAct) may share underlying literature sources and are not fully independent. The cBioPortal, ClinVar, and CIViC records are disease-association annotations that may draw from the same published studies. The literature records (PubMed/Europe PMC) are the most direct external evidence but are also not an independent-cohort replication.

**External statistical validation was not performed** — no independent cohort statistic was supplied. All conclusions about prognostic value beyond this dataset remain hypotheses requiring validation.

## 6. Limitations and alternative explanations

### Limitation 1: Tumor purity and cell composition
The protective immune/ECM signals may reflect the proportion of infiltrating lymphocytes and stromal cells in bulk tumor tissue rather than tumor-cell-intrinsic biology. This is the most likely confounder for the protective associations. **Investigation**: Estimate immune/stromal scores and adjust the Cox models; validate in single-cell or spatial data.

### Limitation 2: Disease severity and treatment exposure
The dataset does not include clinical covariates (stage, grade, receptor status, treatment). The proliferation signature may be a proxy for high-grade, aggressive tumors; the protective immune signature may reflect early-stage disease. **Investigation**: Obtain clinical annotations and perform multivariable analysis.

### Limitation 3: Association versus causation
The HR values are associations with OS, not causal effects. Elevated expression of mitotic genes may be a consequence of proliferation rather than a driver. **Investigation**: Functional perturbation experiments (knockdown/overexpression) in breast cancer models.

### Limitation 4: Batch/platform effects and data processing
The uploaded table does not specify the platform, normalization method, or whether the HRs were adjusted for covariates. If the data come from multiple batches or platforms, the effect sizes may be biased. **Investigation**: Confirm the data processing pipeline; perform batch correction if needed.

### Limitation 5: Broad or nonspecific pathway enrichment
The "cell cycle" and "proliferation" programs are broad and overlap with many other cancer types; they may not be breast-cancer-specific. The risk-associated direction is expected for any proliferative tumor. **Investigation**: Compare against normal breast tissue and against other cancer types; test whether the signature is specific to a breast cancer subtype (e.g., basal-like vs. luminal).

### Limitation 6 (additional): Direction conflict within programs
`RPA2` (replication factor) is protective-associated while `FEN1`, `TIMELESS`, `UHRF1` are risk-associated. This inconsistency within the replication program suggests that the "replication" label may be too broad, or that RPA2's protective direction reflects a different biological role (e.g., in DNA damage response or immune signaling). This needs to be resolved before interpreting the replication program as uniformly risk-associated.

## Final conclusion

The uploaded survival analysis defines a clear prognostic architecture in breast cancer in which a proliferation/mitotic program (AURKA, TPX2, CDC20, UBE2C, ZWINT, and related genes) is consistently risk-associated, while immune-cell and ECM/stromal genes are consistently protective-associated, but these conclusions are based on a single-cohort association analysis, external statistical validation was not performed, and the protective signals in particular may reflect tissue composition rather than tumor-cell-intrinsic biology, so the most defensible next steps are to validate the proliferation signature in an independent breast cancer cohort and to perform cell-type-resolved analysis to distinguish tumor-intrinsic from microenvironment-driven signals.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=27, external claims checked=0, external mismatches=0, status=passed.

Answer model API: deepseek / deepseek-v4-flash.

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 100/100 selected items (records returned); cbioportal 100/100 selected items (records returned); chembl 52/100 selected items (records returned); civic 12/100 selected items (records returned); clinicaltrials 57/100 selected items (records returned); clinvar 100/100 selected items (records returned); ensembl 100/100 selected items (records returned); europepmc 990 articles / initial full-cohort RAG 100 queries + 4 current-round queries; gtex 98/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 99/100 selected items (records returned); humanbase 100/100 selected items (records returned); intact 99/100 selected items (partially returned; some queries failed); mygene 100/100 selected items (records returned); omnipath 65/100 selected items (records returned); opentargets 100/100 selected items (records returned); pubmed 791 articles / initial full-cohort RAG 100 queries + 3 current-round queries; some queries failed; quickgo 99/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 100/100 selected items (records returned)
Local databases: gutmgene 4/100 selected items (records returned); hmdb 31/100 selected items (records returned); string 100/100 selected items (records returned); trrust 40/100 selected items (records returned)
